



September 29, 2026

To whom it may concern:

Company Name:	TOHO HOLDINGS CO.,LTD.
Corporate Representative:	Hiromi Edahiro, Representative Director, President and CEO (Prime Market of Tokyo Stock Exchange Securities Code: 8129)
Contact	Makoto Kawamura, Senior Executive Corporate Officer and General Manager, Corporate Strategy Division (TEL: 81-3-6838-2803)

Notice Regarding Execution of a Basic Agreement with REPROCELL Inc.
Concerning Domestic Distribution of the Stem Cell Product “Stemchymal®”

TOHO HOLDINGS CO., LTD. (Headquarters: Tokyo; Representative Director, President and CEO: Hiromi Edahiro; hereinafter “TOHO HOLDINGS”) is pleased to announce that on September 17, 2026, it executed a basic agreement with REPROCELL Inc. (Headquarters: Kanagawa; Representative Director and CEO: Chikafumi Yokoyama; hereinafter “REPROCELL”) toward a partnership concerning the domestic distribution, etc. of the regenerative medical product “Stemchymal®”, for which REPROCELL is currently applying for marketing approval in Japan, as described below.

1. Purpose of execution of the basic agreement

TOHO HOLDINGS is a corporate group active in the medical, nursing and healthcare fields, engaged in pharmaceutical wholesaling, dispensing pharmacy, manufacturing and sales of pharmaceuticals, and development and provision of customer support systems under the Group slogan “Total Commitment to Good Health”. TOHO HOLDINGS also proactively promotes initiatives for regional medical collaboration, nursing and home care.

On June 24, 2026, REPROCELL submitted an application for manufacturing and marketing approval in Japan for Stemchymal®, with the indication of suppressing the progression of ataxia in patients with spinocerebellar ataxia (SCA3 and SCA6). Under the basic agreement, TOHO HOLDINGS and REPROCELL will discuss and consider the establishment of a supply system for medical institutions nationwide utilizing the pharmaceutical distribution network of the TOHO HOLDINGS Group, as well as a distribution system tailored to the characteristics of regenerative medical products, with the aim of enabling a smooth market launch and stable supply of Stemchymal® following manufacturing and marketing approval.

Through this partnership with REPROCELL, TOHO HOLDINGS will proceed with the establishment of a system capable of stably supplying the product to medical institutions nationwide, and will make every effort to deliver a new treatment option to patients battling spinocerebellar ataxia as soon as possible.

2. Overview of REPROCELL

- | | |
|------------------------|---|
| (1) Company name : | REPROCELL Inc. |
| (2) Location : | 3-8-11 Shin-yokohama, Kohoku-ku, Yokohama, Kanagawa, Japan |
| (3) Representative : | Chikafumi Yokoyama, Representative Director and CEO |
| (4) Established : | February 26, 2003 |
| (5) Business content : | i. Research Support Business: Manufacture and sale of iPS cell-related research reagents; provision of drug discovery support services; provision of human biospecimens; provision of genetic analysis services
ii. Medical Business: Clinical laboratory testing services; development of regenerative medical products |
| (6) Capital : | 2,720 million yen (as of March 31, 2026) |

3. Forward looking outlook

While we expect that this transaction will have only a negligible impact on consolidated earnings of TOHO HOLDINGS, we believe that it will contribute to increase the Group’s corporate value over the medium to long term. The Company will disclose any impact promptly if it becomes necessary to do so in the future.

Note: This document has been translated from the Japanese original for reference purposes only.
In the event of any discrepancy between this translated document and the Japanese original, the original shall prevail.